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                                        ABSTRACT 
 
INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is a complex disease characterized 
by airflow limitation resulting from airway inflammation, parenchymal destruction 
and the development of emphysema. COPD results from inflammatory 
mechanisms, the “SPILL-OVER” of inflammatory mediators like IL6, IL-8, 
TNF-∝ leads to systemic inflammation and also initiates or worsens comorbid 
diseases. About 15-30% of COPD patients have anemia and this is noticed 
especially in patients with severe disease, and the occurrence of polycythaemia is 
only 6%. Anemia is related to depressed functional capacity and for low quality 
and standard of life.  
METHODOLOGY 
This clinical observational study was undertaken to investigate the pattern and 
magnitude of Hematological parameters in the relationship with the severity of the 
disease by Forced Expiratory Volume1 (FEV1). 60 Patients were included in this 
study. 
 
All the Patients were subjected to detailed History and Physical examination. Lung 
function parameters were assessed with the help of spirometer. All patients 
underwent Haematological parameters with particular reference to HB%, MCV, 
MCH, MCHC, HAEMATOCRIT, and PERIPHERAL SMEAR along with routine 
tests. 
RESULTS AND DISCUSSION 
In our study, 56% of patients had anemia, among them 70% had Normocytic 
Normochromic Anemia and 30% had Microcytic Hypochromic Anemia. Patients 
with duration of illness 6-10 yrs had 57% risk for anemia and > 10 yrs had 87% 
risk for anemia. Patients with history of exposure to Cotton mill dust had 71% risk 
for anemia. 
CONCLUSION 
Patients with decreased FEV1, having prolonged duration of illness and increasing 
grades of dyspnea had high risk for anemia. Patients with exposure to Cotton Mill 
dust and with the history of smoking had increased risk for anemia, but its 
association was not statistically significant. 
KEY WORDS 
 COPD 
 ANEMIA 
 FEV1 
 
 
INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is a complex 
disease characterized by airflow limitation resulting from airway 
inflammation, parenchymal destruction and the development of 
emphysema. COPD results from inflammatory mechanisms, the “SPILL-
OVER” of inflammatory mediators like IL6, IL-8, and TNF-∝ leads to 
systemic inflammation and also initiates or worsens comorbid diseases. So 
the comorbities complicate the management of COPD and need to be 
evaluated carefully1. Diseases with higher morbidity in COPD are 
associated with an increased risk of hospital admissions,mortality and 
healthcare costs2-3. According to World Health Organisation, in 2020 
COPD will become the 3 rd leading cause of death. Meta-analysis study in 
India suggests that the prevalence of COPD above 30 yrs in males is 5% 
and in females is 2.7%. 
According to a study,  about 15-30%  of COPD  patients  have  
anemia and this  is noticed especially in patients with severe disease, and  
the occurrence of polycythaemia  is only  6% 4-6 . Anaemia is related to 
depressed exercise capacity along with functional dyspnea.This is a 
significant reason for depressed functional capacity and for low quality and 
standard of life.7-9 
 
 
Forced Expiratory Volume in one second (FEV1) is an objective 
measurement,viewed as the most accurate predictor of  severity  of  airway 
obstruction. The advantage of FEV1 is that it requires lesser effort to 
measure and can be   carried out in all stages of COPD patients .COPD 
progression can be assessed by serial measurements of FEV1. In this 
dissertation an effort is made to assess the hematological manifestations in 
COPD Patients and the relationship to FEV1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
OBJECTIVES OF THE STUDY 
 
To study the Haematological manifestations in relation to  FEV1 in 60 
cases of   Chronic Obstructive  Pulmonary Disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      
  
 
 
REVIEW OF LITERATURE 
 
HISTORY OF COPD 
 
 Empysema  goes  for description with  hierarchial reference  as follows:   
“Voluminous lungs”  was widely explained by Bonet in 1679; 
 Morgagni’s (1769)   showed the lungs were “turgid”, particularly from 
air. 
 
                                             
       
 
 
FIG 1: TEOFILO BONET    FIG 2: GIAMBATISA MORGAGNI 
(1620 -1689)                                (1682-1771) 
Baille's descriptions about the emphysematous lung, was exactly similar 
to Samuel Johnson’s one. 
The emergence of our clinical apprehension of the chronic bronchitis rose 
from Badham (1814), who attributed chronic cough and mucus 
hypersecretion jointly to the word "catarrh".10 
Percussion probably got developed as a way of ascertaining how much 
fluid remained in barrels of wine by Austrian physician Josef Leopold 
Auenbrugger who applied percussion of chest, having learned this method 
in his father’s wine cellar.11 
 
 
 
                     FIG 3: Josef  Leopold Auenbrugger (1722-1809) 
 
Laennec, the inventor of  Stethescope ,in 1821, explained exhaustively 
about Emphysema   in his  “Treatise of Diseases of the Chest”         
 
 
 
 
FIG 4: “Treatise of Diseases of the Chest”. 
In 1846, John Hutchinson (1811-1861)  invented  spirometer  and  he 
described the  values of  vital capacity in measurement.  
 
FIG 5 : SHADOW IMAGE OF JOHN HUTCHINSON AND 
HIS SPIROMETRY 
 
 
 Tiffeneau ten decades later, mentioned Timed Vital Capacity as a 
parameter in Spirometry. 
 Gaensler  introduced the concept of  Forced Vital Capacity ,which 
forms the foundation  for  FEV1 and FEV1/FVC.10 
 In 1916, Osler’s Principles and Practices of Medicine   describes 
“EMPHYSEMA” 
 In 1956, Barach and Bickerman presented the first comprehensive 
text book on “Pulmonary Emphysema”. 
 
 
 
 
 
 
  
 
 
DEVELOPMENT OF THE RESPIRATORY SYSTEM12-17 
The human developmental phases between fertilization and birth are 
generally divided into  
 
                      Embryonic Period     Fetal period 
The embryonic period occurs during the first 8 weeks and is 
traditionally organized into 23 stages. During the embryonic period, all 
major organs begin their development.  
The fetal period occurs during the remaining32 weeks of gestation. 
During this period, the organs continue to develop and refine their structure 
and function. 
There are three  embryologically  germinal tissue layers that eventually 
forms all tissues and organ. 
 ENDODERM 
 MESODERM 
 ECTODERM 
During the development, lung bud forms the trachea and two lateral 
out pocketings, the bronchial buds. At the beginning of the fifth week, each 
of these buds enlarges to form right and left main bronchi. The right then 
forms three secondary bronchi, and the left forms two secondary bronchi. 
The mesoderm, which covers the outside of the lungs, develops into 
the visceral pleura. The somatic mesoderm layer, covering the body wall 
from the inside, becomes the parietal pleura. The space between the parietal 
and visceral pleura is   pleural cavity.  
 
 
 
FIG 6: DEVELOPMENT OF THE RESPIRATORY SYSTEM 
During further development, secondary bronchi divide repeatedly in 
a dichotomous fashion, forming ten tertiary (segmental) bronchi in the 
right lung and eight in the left, creating the bronchopulmonary segments of 
the adult lung. By the end of the sixth month, approximately 17 generations 
of subdivisions have formed. Before the bronchial tree reaches its final 
shape, however, an additional six division’s form during postnatal life. 
MATURATION OF THE LUNGS 
Up to the seventh prenatal month, the bronchioles divide 
continuously into more and smaller canals, and the vascular supply 
increases steadily. Respiration becomes possible when some of the cells of 
the cuboidal respiratory bronchioles change into thin, flat cells. These cells 
are intimately associated with numerous blood and lymph capillaries, and 
the surrounding spaces are known as terminal sacs or primitive alveoli. 
During the seventh month, sufficient numbers of capillaries are present to 
 
 
guarantee adequate gas exchange, and the premature infant is able to 
survive. 
During the last 2 months of prenatal life and for several years 
thereafter, the number of terminal sacs increases steadily. Mature alveoli 
are not present before birth. In addition to endothelial cells and flat alveolar 
epithelial cells, another cell type develops at the end of the sixth month. 
These cells, type II alveolar epithelial cells, produces surfactant, a 
phospholipids-rich fluid capable of lowering surface tension at the air-
alveolar interface. 
Before birth, the lungs are full of fluid that contains a high chloride 
concentration, little protein, some mucus from the bronchial glands, and 
surfactant from the alveolar epithelial cells. The amount of surfactant in 
the fluid increases, particularly during the last 2 weeks before birth.As 
concentration of surfactant increase during the 34th week of gestation. 
FIG 7: MAJOR PHASES OF RESPIRATORY DEVELOPMENT 
 
 
 
 
Throughout the developmental period, lung growth is similar in 
male and female fetuses. A full-term newborn has about 50 million alveoli, 
and the number continues to elevation for about 2 to 3 years after birth. 
The developmental branching process of the airways and blood vessels of 
the lung is highly regulated by the timely activation various genes in 
different locations. Of the approximate 22,000 genes in the human genome, 
about 40 are required for normal respiratory development.  
                                                             
  
 
 
ANATOMY18 
UPPER RESPIRATORY TRACT 
The Upper respiratory tract includes nose, pharynx, paranasal 
sinuses and larynx.  The nose is lined with ciliated epithelium helps in 
clearance of particles and microorganisms.  
Functions of the upper airway: 
 Passageway for gas flow 
 Filter 
 Heater 
 Humidification 
 Phonation 
 Protection of airways 
 Sense of smell and taste 
LOWER RESPIRATORY TRACT 
Trachea 
  It extends down from cricoid cartilage and bifurcates in the superior 
mediastinum at the level of angle of  Louis. The adult trachea is 
approximately 12cm long and has inner diameter of 2cm. It is lined by 
pseudo stratified ciliated columnar epithelium containing  goblet cells.  The 
adult has 16 to 20 cartilaginous  ring.The cartilaginous rings armor the 
trachea so that it does not collapse during exhalation. 
 
 
 
BRONCHI AND THEIR DIVISIONS 
 
 
FIG 8: BRONCHI AND THEIR DIVISIONS 
 
At the base of the trachea, Carina is a landmark where the trachea 
bifurgates. The left bronchus branches with an angle of about 45 to 55 
degrees and runs more horizontally and is about 5 cm long. The right main 
bronchus branches with an angle of about 20 to 30 degrees and it is only 
about 1 to 2.5 cm and is a more direct continuation of trachea.  
  
  
 
 
BRONCHOPULMONARY SEGMENTS 
 
FIG 9: BRONCHOPULMONARY  SEGMENTS 
 
 
INTRA PULMONARY AIRWAYS  are divided  in to three major 
groups 
1) BRONCHI-has cartilage and serve as a airway 
2) MEMBRANOUS BRONCHIOLES- non-cartilaginous airways   
3) RESPIRATORY BRONCHIOLES-serve as a airways and for gas 
exchange 
There are about 28 generations of  Tracheobronchial  tree  which serve as 
a Conducting zone  and  Respiratory zone  
FIG 10: STRUCTURES OF THE LUNGS 
  
 
 
ALVEOLI 
  There are about two hundred to six hundred million alveolus, which 
is called as the terminal respiratory unit. 
There are two types of epithelial cells lining the alveoli. 
 Type 1 cells are flat squamous epithelial cells and are the primary 
lining cells. 
 Type II cells Granular Pneumocytes are rounded secretary cells and 
contain numerous lamellar inclusion bodies. These cells secrete 
surfactant. 
The Bronchi and their Innervations 
The trachea and bronchi have cartilage in their walls, but relatively 
little smooth muscle and it is lined by a ciliated epithelium. It has both 
mucus gland and serous glands. Ciliated structure is present up to 
respiratory bronchioles, but glands are absent from the epithelium of the 
bronchioles and terminal bronchioles and their walls do not contain 
cartilage. However, their walls contain more smooth muscle and they are 
innervated by the autonomic nervous system. There are abundant 
muscarinic receptors and cholinergic discharge causes 
bronchoconstriction. There are β1 and β2 adrenergic receptors in the 
bronchial epithelium and smooth muscle and in mast cells. Many are not 
innervated. Some may be located on cholinergic endings and ganglia, 
where they inhibit acetylcholine release. In humans, the β2 receptors 
predominate and inhaled or injected β agonist such as isoproterenol cause 
bronchodilation and depressed bronchial secretion. 
  
 
 
PULMONARY CIRCULATION19 
 
 
FIG 11: PULMONARY CIRCULATION 
All the venous blood in the body enters 
     RIGHT ATRIUM 
 
 RIGHT VENTRICLE 
  
PULMONARY ARTERY 
 
 PULMONARY CAPILLARIES –OXYGENATION  OCCURS 
 
PULMONARY VEIN 
 
 LEFT ATRIUM  
 
LEFT VENTRICLE 
 
SYSTEMIC CIRCULATION  
 
 
 
The separate and much smaller bronchial arteries come from 
systemic arteries. They form capillaries, which drain into bronchial vein or 
anastomose with pulmonary capillaries or veins. The bronchial veins drain 
into the azygos vein. The bronchial circulation nourishes the bronchi and 
pleura.  
 
LYMPHATIC SYSTEM 
    Lymphatic channels are more abundant in the lungs than in any other 
organ. 
     
                  Lymphatics of the lung is divided in to two plexus 
 
 
            SUPERFICIAL PLEXUS      DEEP PLEXUS 
 
 Superficial plexus is present  in the  visceral pleura  
 Deep plexus is located  in  peri broncho vascular connective 
tissues 
 Alveolar wall devoid of  lymphatics 
 Lymph is flow  towards hilum from there it drains in to the  
 extrapulmonary lymph nodes.   
 
 
 
 
 
 
  
 
 
PHYSIOLOGY 20-21 
 
FIG 12: LUNG VOLUMES AND CAPACITIES 
Lung volumes 
1) Tidal volume: The amount of air that moves into the lungs with each 
inspiration (or the amount that moves out with each expiration) is 
called the tidal volume.(Value  500-750 ml). 
2) Inspiratory reserve volume: The air inspired with a maximal 
inspiratory effort in excess of the tidal volume. (Value -2 litres). 
3) Expiratory reserve volume: The volume expelled by an active 
expiratory effort after passive expiration is the expiratory reserve 
volume.(value -1 litre). 
4) Residual volume: The air left in the lungs after a maximal 
expiratory effort (value -1.3litres). 
5) Vital capacity: The largest amount of air that can be expired after a 
maximal inspiratory effort, is frequently measured clinically as an 
index of pulmonary function (value -3.5 litres). 
6) Inspiratory capacity: The maximum amount of air inspired from 
the end-expiratory level (IRV+ TV)(Value -2.5 litres). 
 
 
7) Functional residual capacity:The volume of the air remaining in 
the lungs after expiration of a normal breath (RV+ ERV).(Value -
2.5 litres). 
8) Total lung capacity: The total lung capacity is composed of all the 
four components of Tidal volume, Inspiratory reserve volume, 
expiratory reserve volume and Residual volume (Value - 5 litres). 
 
FEV1, timed vital capacity: The fraction of the vital capacity expired 
during the first second of a forced expiration. 
 
Respiratory minute volume: The amount of air inspired per minute. It is 
normally6 litres (500ml / breath × 12 breath / min) 
 
Maximal Voluntary Ventilation: It is the largest volume of gas that can 
be moved into and out of the lungs.  In one minute by voluntary effort. The 
normal MVV is 140-180 L/min for a healthy adult male. 
 
Three measurements are commonly made from a recording of FORCED 
EXHALED VOLUME VERSUS TIME,i.e. a spirogram. 
 
1. FEV1 (Forced expired volume in one second): the volume of air 
expired in the first second of maximal expiration after a maximal 
inspiration. This is a measure of how quickly the lungs can be 
emptied. 
2. FVC (Forced vital capacity): maximum volume of air that can be 
exhaled during a forced maneuver. 
3. FEV1/FVC: FEV1 expressed as a percentage of the FVC, gives a 
clinically useful index of airflow limitation. 
 
  
 
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
DEFINITION22 
Chronic obstructive pulmonary disease (COPD) by definition goes 
as abnormalities in expiratory flow tests that do not alter significantly over  
several months of observation  and this helps  to distinguish COPD from 
asthma. 
 Two disorders are mentioned in COPD:  
 EMPHYSEMA 
 CHRONIC BRONCHITIS 
American Thoracic Society (ATS) defines COPD as23 
       “A disease state characterized by the presence of airflow limitation due 
to chronic bronchitis are emphysema; the airflow obstruction is generally 
progressive, may be accompanied by airway hyperreactivity that may be 
partially reversible”. 
 The Global initiative for Chronic Obstruction Lung Disease 
(GOLD) classified COPD as “A disease state characterized by airflow 
limitation that is not fully reversible. The airflow limitation is usually both 
progressive and associated with an abnormal inflammatory response of the 
lungs to noxious particles or gases”. 
 The components of COPD are Chronic bronchitis and 
Emphysema24. 
 
 
Chronic bronchitis is defined as “the presence of a chronic productive 
cough on most days for three months, in each of two consecutive years”. 
 
Emphysemais defined as “abnormal, permanent enlargement of the distal 
air spaces, distal to the terminal bronchioles, accompanied by destruction 
of their walls and without obvious fibrosis”. 
 
 Cigarette smoking is the highest  risk factor for COPD. The studies have 
shown a strong relationship between smoking and COPD, in many a high 
proportion of nonsmokers also develop COPD. There is an inverse 
relationship between cigarette consumption and expiratory flow rate. The 
cessation of smoking slows down the speed of pulmonary function 
deteriorations to that of nonsmokers, but do not normalize the lungs 
function. 
 The passive smoking, in other words, environmental tobacco smoke 
(ETS), or second hand smoke, is associated with COPD. Indoor air 
pollution due to domestic cooking and heating has been associated with 
chronic respiratory symptoms as reported from many developed and 
developing countries.  
Occupational exposures to dusts alone or to dusts and in association 
with fumes and vapors are the risk factors for COPD. 
 
 
The most important factors were age, daily cigarette consumption, 
possible alterations of smoking habits and the observed value of FEV1. 
        Smoking results in an over production of proteases (i.e. elastase). 
Further, it inactivates the anti-elastases. Thus there is an imbalance 
between the protease-antiprotease with resultant excess action of protease, 
which leads on to the destruction.  
EPIDEMIOLOGY25-28 
PREVALENCE:  Most data available on COPD statistics are from 
developed countries, acquiring accurate epidemiological data on COPD is 
very tough and costs much.  
 
A meta-analysis   in performed between 1990 and 2004 in 28 
countries showed the prevalence was 11% in men and 5% in women and 
3.9% in never smokers and 15.2% in smokers. 
 
Halbert et al. reviewed 32 prevalence studies from 17 different countries 
and concluded that prevalence of COPD ranged between 4 to 10%. 
 
COPD IN INDIA29-31 
The inference of the INDIAN STUDY INSEARCH phase II was 
released and this studies show that the prevalence of COPD in India was 
3.7% (4.5% males and 2.9% females). 
 
 
Wig (1964) et al. showed prevalence of COPD to be 3.36% and 
2.54% in men and women with 2:1 smoker non smoker ratio in rural Delhi. 
 
Viswanathan (1966) et al. showed prevalence of 2.12% and 1.33% 
in men and women respectively in a study in Patna. 
In a pilot study in rural area of Mysore, prevalence of COPD was 
7.1%, 11.1% in males and 4.5% in females.  
Jindal (1993) et al. in a study in rural population of North India 
showed Prevalence of 6.2% and 3.9% in males and females respectively. 
In urban population of North India showed prevalence of 4.2% and 1.6% 
in males and females respectively with smoker to nonsmoker ratio of 9.6.32  
 
Ray (1995) et al. in a study in South India showed prevalence of 
4.08% and 2.55% in males and females respectively with smoker to 
nonsmoker ratio of 1.6. 
 
Malik et al. (1986) in a study in rural population of  North  India 
showed Prevalence of 9.4% and 4.9% in males and females respectively 
with smoker to non smoker ratio of 5.5. In urban population of North India 
showed prevalence of 3.7% and 1.6% in males and females respectively 
with smoker to non smoker ratio of 3.7. 
 
 
 
 
 
RISK FACTORS OF COPD 
 
 
 
                                       FIG 13: RISK FACTORS OF COPD 
 
Tobacco smoking  
It is a familiar fact that Tobacco smoke comprises more than 4000 
toxic chemicals, including 50 known carcinogens33 
A data showed that low-tar cigarettes have irreconcilable effect on 
COPD and any volume of smoking is harmful 34 
 
Environmental Tobacco Exposure or Passive Smoking 35 
Exposure to cigarette smoke or passive smoking is gaining more 
attention because of its appreciable public health effects. Environmental 
tobacco smoke is a combination of side-stream smoke and exhaled 
 
 
mainstream smoke. Owing to a lower temperature of combustion, side 
stream smoke contains larger concentrations of  
 Ammonia,  
 Benzene,  
 Carbon-monoxide, 
 Nicotine, 
 and various carcinogens(2-naphthylamine, 4-aminobiphenyl,                      
n-nitrosamine, benza-anthracene, and benzopyrene) than the 
mainstream smoke.  
 
In enclosed spaces, smoke accumulates, and the concentration varies 
with the number of smokers, with the type of smoking, and with the 
characteristics of the room, especially the ventilation. 
 
Gupta D et al. in a Multicentric Population Study from India 
concluded that Passive smoking is associated with increased prevalence of 
respiratory symptoms. 
 
  
 
 
OCCUPATIONAL EXPOSURE 36 
Epidemiological data by the Matheson et al. in their study of 1232 
people concluded that occupational exposure to biological dust was 
associated with elevated risk of COPD which was higher in women. 
Bushra Iftikhar and his colleagues in Peshawar studied relationship 
between silica exposure and COPD and concluded that people exposed to 
silica dust for more than 10 years, and daily exposure of >8 hours had more 
risk of developing COPD. 
 
BIOMASS FUEL EXPOSURE 37-38 
The combustion of biomass fuel   releases several toxic gases and 
causing respiratory problems.  
 
Mrigendra Raj Pandey in his study in Nepal showed increased 
prevalence in females exposed to biomass fuel exposure and the severity 
of symptoms correlated with duration of exposure to smoke.  
 
Orozco-Levi M et al in a case control study of 120 females in 
Barcelona, Spain showed increased risk of COPD in exposure to wood or 
charcoal smoke.  
 
 
 
 
ALPHA-1 ANTITRYPSIN DEFICIENCY 39-40 
The only known genetic cause of emphysema is Alpha-1 antitrypsin 
(AAT) deficiency. An inherited deficiency of a protein in the blood called 
the α1-antitrypsin (AAT). It is the only known genetic disorder that leads 
to COPD. AAT deficiency accounts for less than 1 percent of COPD in 
USA. This deficiency is an autosomal hereditary disorder in which there 
are low levels of α1-antitrypsin in serum and lungs, with a high risk of 
development of panlobular emphysema in the third to fifth decade. There 
is an increased risk of development of liver disease in the childhood 
associated with this condition.  
AAT is a glycoprotein coded for by a single gene on chromosome 
14. It is a serine protease inhibitor with primary function of inhibiting 
neutrophil elastase. Emphysema results from an imbalance between the 
neutrophil elastase in the lung and the anit-elastases. 
This concept is known as the “elastase-antielastase balance 
hypothesis of Emphysema.” 
Many Indian studies have tried to examine the role of alpha-
1antitrypsin deficiency in the causation of COPD and is summarized by 
Malik et al.The heterozygote state (intermediate) was found to be 10.3 to 
23.3 percent and homozygous (severe) state in 2.8 to 20 percent of cases 
of COPD. 
 
 
 
 
Αlfa 1-Antitrypsin Deficiency Screening 
In patients of Caucasian descent who develop COPD at a young age 
(< 45 yr) or who have a strong family history of the disease, it may be 
valuable to identify coexisting α1-antitrypsin deficiency. This could lead to 
family screening or appropriate counseling. 
Young patients with severe hereditary α1-antitrypsin with severe 
hereditary α1-antitryspin augmentation therapy. However, this therapy is 
very expensive, not available in most countries, and not recommended for 
patients with COPD that is unrelated to α1-antitrypsin deficiency. 
  
 
 
THE OVERLAP OF COPD AND ASTHMA 
  Active asthma patient have TEN fold risk of Chronic bronchitis 
and SEVENTEEN fold risk of Emphysema. 
 
FIG 14a : THE OVERLAP OF COPD AND ASTHMA 
                             
 
 
FIG 14b : THE OVERLAP OF COPD AND ASTHMA 
Respiratory Infections: Childhood respiratory infections have been 
assessed as potential predisposing factor for the eventual development of 
COPD. 
 
 
 
MECHANISMS OF AIRWAY OBSTRUCTION IN COPD 
 
 
FIG 15 : MECHANISMS OF AIRWAY OBSTRUCTION IN COPD 
The three mechanisms account for the elevation in peripheral airways 
resistance in patients with COPD.  
i) The loss of elasticity of the lungs in emphysema allows the airways to 
narrow 
ii) The airways narrow because the supporting alveolar attachment are                
destroyed by the emphysematous process 
iii) The inflammatory process in the airways thickens the wall and narrows               
the lumen of the distal airways. 
 
  
 
 
PATHOLOGY 41-43 
 Several of the abnormalities in chronic bronchitis and emphysema 
occur in large bronchi (airways with cartilages in their walls and more than 
2 mm in diameter), bronchioles (no cartilages in their walls and less than 2 
mm internal diameter), and parenchyma. Since emphysema and chronic 
bronchitis are invariably associated in the same patient, it is common to 
find changes in all the above three components, although one or the other 
change may predominate. 
 The important change in the large bronchi is the hypertrophy of the 
mucus secreting glands in the sub epithelial layer that are enlarged and are 
thought to secrete most of the mucus found in the airways. The hypertrophy 
can be measured as the thickness of the gland layer in histological sections 
and comparing it to that of the bronchial wall and is expressed as Reid 
index. The mucous gland hypertrophy is largely seen in the larger bronchi 
and is equally present throughout the lungs. The mucus secreting goblet 
cells are also elevated in number in the large as well as in the bronchioli. 
Bronchial muscle hyperplasia is present in patient with COPD. 
 The increasing amount of muscle may be responsible for the airway 
hyper reactivity seen in this patient. Emphysema are classified as, 
(a) Centriacinar Emphysema  affects the respiratory brochioles . This is 
probably secondary to bronchiolitis. It is commoner at the lung apices. 
(b) Panacinar (or) Panlobular Emphysema. All components of the acinus 
are involved about equally. usually related with ∝1 antiprotease 
deficiency. It can also occur in bases of the lung. 
(c) Distal Acinar Emphysema (or) Paraseptal emphysema predominantly 
involvs the alveolar ducts and sacs. 
 
 
 
PATHOGENESIS 43 
 
FIG 16: SYSTEMIC MANIFESTATIONS OF COPD 
 
 
 
FIG 17 : PATHOGENESIS OF COPD 
  
 
 
Inflammatory markers-Cytokines in COPD 
 Interleukin-6  
 TNFα 
 IL-1β 
 Chemokines- CXCL8 (IL-8) are released during the course of 
illness and during acute exacerbations of COPD patients and these 
cytokines are responsible for systemic inflammation and leads to 
weight loss,cardiac failure ,normocytic anaemia etc.  
CLINICAL FEATURES OF COPD 44-49 
The usual presentation is at the fifth decade of life. The characteristic 
symptoms of chronic bronchitis are cough with expectoration, wheeze, and 
breathlessness. The cough and expectoration are usually exacerbated from 
time to time particularly more during the winter. 
Pure emphysema is mainly manifested as breathlessness and 
wheezing, cough and expectoration are less important symptoms. The 
patient gives a history of progressive dyspnea, sometimes starting 
apparently after a mild infection and following exertion or exercise. 
Airflow obstruction causes dyspnea and by the time this present, the FEV 
is about 1 liter or less than 50 percent of the predicted value. The course 
progresses over the next 5 year or more with further loss of FEV. The 
 
 
patient will try to breathe with pursed lips to utilize the respiratory muscles 
maximum. 
Corpulmonale  is more common in chronic bronchitis, this is less 
common in emphysema except terminally. Respiratory failure is the 
common mode of death of emphysema patients. The emphysema patient 
maintains a near normal 𝑷𝒂𝑶𝟐 and normal 𝑷𝒂𝑪𝑶𝟐 by hyperventilation 
until a late stage of the disease. 
 
 
FIG 18: CAUSES OF EXACERBATION OF COPD 
  
 
 
m MRC GRADING DYSPNOEA 50 
 
SYSTEMIC MANIFESTATIONS AND CO-MORBIDITIES OF 
COPD 
 
 
 
  
 
 
PHYSICAL SIGN 44-49 
  In early stage of the disease there may not be any findings on 
examination. In later stages, there will be emaciation, cyanosis, anaemia, 
edema, and raised jugular venous pressure, if there is associated 
corpulmoale and heart failure. 
 The chest is barrel shaped with kyphosis, elevated anteroposterior 
diameter, ribs being set more horizontal and these changes are permanent 
and one may feel an inspiratory tracheal tug due to the contraction of low, 
flat diaphragm. The movement of the chest wall is reduced with limited 
expansion. The patient may use his accessory muscles of respiration.  
 
JVP may be seen during expiration. In the more severe cases, the 
costal margins will be drawn inwards on inspiration, paradoxically, due to 
the pull of the low, flattened diaphragms. On percussion reveal 
hyperresonant due to hyperinflation of lungs. On auscultation there is a 
prolonged expiratory phase, wheeze and crepitations are heared. 
 
Airflow obstruction is detected by placing the chest piece of the 
stethoscope over the trachea and timing of a forced expiration. Normally it 
is possible to empty the lungs in 4-5 seconds, but a patient with airflow 
obstruction shows a prolonged expiratory time. Patients with end stage 
COPD may adopt positions that relieve dyspnoea, by leaning forward with 
neck extended   called asTripod sign. The accessory respiratory muscle 
helps in to keep the airway patent. Expiration often takes place through 
pursed lips. Paradoxical in drawing of the lower intercostals space is often 
evident (Hoover's sign), cyanosis may be present; clubbing is not 
associated with COPD. If it present one should rule out bronchiectasis or 
lung carcinoma. An enlarged, tender liver indicates heart failure due to 
 
 
elevated intrathoracic pressure. Asterexis may be seen with severe 
hypercapnia. 
COPD patients usually ail from muscle wasting, loss of body 
weight and low quality of life.  
 
 
 
 
 
 
 
PULMONARY FUNCTION TESTING.51-52 
Pulmonary function evaluation not only establishes the diagnosis of COPD 
but also assesses the  progression and severity of  COPD.  
 
FIG 19: SPIROMETRY 
Spirometry is performed in the following individuals  
 Unexplained dyspnea or suspicion of COPD 
 Screening of habitual smokers for early detection 
 Repeat spirometry after medications to detect the 
reversibility.  
 Guidelines for rational therapy 
  
 
 
 
 
FIG 20: CLASSIFICATION OF SEVERITY OF COPD 
 
                     FIG: 21 DYNAMIC FLOW –VOLUME LOOPS 
 
 
PROGNOSIS 53-54 
 Long term prospective studies in patients with severe COPD with 
FEV of less than 1 liter have shows 
 5 yr survival rates - 69 % 
 10 yr survival rates - 40%  
 
The presence of radiological evidence of emphysema or of bullae 
in one study resulted in five-year mortalities of 53 percent and 70 
percent respectively. Right ventricular failure carries a poor 
prognosis with a five mortality of 60 to 80 percent reported in 
different studies. Right ventricular systolic pressure of > 35 mm H, 
FEV of < 30 percent of predicted and age > 70 years is other poor 
prognostic factors. 
 Three risk factors have been useful in predicting the outcome of a 
patient with COPD age, smoking status, and FEV. The studies of prognosis 
in the National Institutes of Health Intermittent Positive Pressure Trial 
confirmed the findings of earlier studies that age and initial FEV are 
powerful predictors of outcome. The only consistent predictor of decline 
in FEV besides the initial FEV is the bronchodilator response of the patient. 
The larger the response the slower the decline in FEV and this relation is 
not dependent on the initial FEV. 
 In persons with FEV < 0.75 L, mortality rate at 
 1 yr   -  30 %  
 10 yr -  95% 
 
 
 
 However, some patients with severe airflow obstruction may survive 
longer, and even up to 15 years. Some other data suggest that next to 
cessation of smoking, a higher degree of reversibility of airflow obstruction 
and a lower degree of airway reactivity are the two most important 
predictors of a slower decline in FEV.  
 
BODE INDEX FOR STAGING COPD 55 
 
FIG 22: BODE INDEX FOR STAGING COPD 
BODE INDEX PREDICTS  
 PROGNOSIS 
 DEATH AND HOSPITALIZATION BETTER THAN FEV1 
ALONE 
 
 
 
INVESTIGATIONS 
Sputum Examination 56-58 
Sputum Examination is done to all patients with cough of > two wks 
as per RNTCP Guidelines because Smoking not only increases the risk of 
COPD and tuberculosis (TB).  
Pulse Oximetry 59-60 
Pulse oximetry is to asses hypoxaemia during acute exacerbation of 
COPD and in respiratory failure cases. 
 
Chest X-Ray61-62 
A plain Chest X-Ray in both posteroanterior and lateral view to be done.   
 
 
 
 
 
 
 
 
FIG 23: CHEST X-RAY OF COPD 
 
 
 
 
 
Five radiologic criteria have been described to diagnose 
emphysema. 
(i) A retrosternal space (greatest distance from the sternum to the 
anterior heart silhouette) more than 2.54 cm(lateral radiograph) 
(ii) Regular or irregular hyper-lucency of  lung fields reflecting 
attenuated pulmonary vessels 
(iii)  Low (mid diaphragm below tenth posterior intercostals space) 
and flat diaphragm (for two thirds of their length) on lateral films 
(iv)  Low (mid diaphragm below tenth posterior intercostal space) 
and flat (for two thirds of their length) on PA radiograph 
(v)  Bullae one or more clear walled lesions not considered to be a 
cavity.  
 
Radiologic emphysema is considered to be present when two criteria 
are present. 
 
 
  
 
 
CT CHEST 63-64 
Even in normal study of chest xray, CT Scan identifys emphysema. 
Computerized tomography is usually not necessary routinely in patients 
with uncomplicated emphysema.  
Early emphysema is identified and quantified by HRCT.  
Detailed cardiopulmonary exercise testing (CPET) is helpful in 
assessing65-66 
 Prognosis 
 Functional status for exercise restrictions 
 Impact of therapeutic interventions 
 6-minute walk test (6MWT) is the surrogate for  CPET 
Alpha -1 Antitrypsin Deficiency39 
   Western data shows   that 3% of COPD patients have AAT 
deficiency and there is no such data available in our country. 
  
 
 
TREATMENT GOALS IN A PATIENT WITH STABLE CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE 
 
 
NON-PHARMACOLOGICAL MANAGEMENT OF COPD 67 
 SMOKING CESSATION 
 PULMONARY REHABILITATION 
 OXYGEN THERAPY 
 NON-INVASIVE VENTILATION 
 SURGERY 
SMOKING CESSATION 68-73 
The most important method to prevent COPD and reduces the frequency 
of exacerbations. 
A variety of pharmacotherapies are available to quit smoking. 
 
 
 
Nicotine replacement therapy:   
Available in the form of 
 Chewing gums 
 Tablets 
 Patches 
 Nasal sprays 
 Lozenges 
 Inhalers 
 
 
 
 
FIG 24 : NICOTINE PATCH             FIG 25: NICOTINE INHALER 
 
Bupropion:         
It is the nicotine receptor antagonist; a weak norepinephrine -
dopamine reuptake inhibitor in the brain. 
Carenicline:  
Acts by partial agonist of the nicotinic receptor as well as 
simultaneously blocks it. 
  
 
 
ROLE OF PHYSICAL REHABILITATION74 
 
FIG 26: ROLE OF PHYSICAL REHABILITATION 
OXYGEN THERAPY 75-77 
The oxygen therapy is helpful in reduction of symptoms especially 
in patients with systemic complications. 
INDICATIONS FOR LONG TERM OXYGEN THERAPY 
I .Continous  O2 
1. Resting  pa O2<_ 55 mm Hg 
2. Resting  pa O2  56-59 mm Hg or SaO2 89% in the presence of any of 
the following 
A. Dependent oedema suggesting Congestive Cardiac Failure 
B. P pulmonale in ECG(P wave > 3mm in standard leads II, III, aVf) 
C. Erythrocytosis (heamatocrit>56%) 
 
 
(a) Reimbursable only with additional documentation justifying O2  
prescription and a summary of more conservative therapy that has 
failed. 
II. Non - Continous O2 
1. O2 flow rate and number of hours per day must be specified. 
2. During exercise Pa O2<55mmHg or Sa O2 <88% with associated 
complications, such as pulmonary hypertension, daytime somnolence 
or cardiac arrhythmias. 
NON-INVASIVE VENTILATION 78-81 
NIV is well established in the treatment of Acute Exacerbation of 
COPD patients, and its controversial in stable COPD. 
 Benefits of NIV are 
 Maximum inspiratory pressure 
 Gas exchange 
The indications for NIV in stable COPD are 
1.  Diagnosed case of COPD, optimization of other therapies and 
exclusion of sleep apnoea if required. 
2. Presence of  both  symptoms like fatigue, dysponea, morning 
headache, etc.), and physiologic criteria (one of the following): 
(a) PaCO2≥55 mmHg or PaCO2 of 50-54 mmHg and nocturnal 
desaturation (oxygen saturation by pulse oximeter≤88% for five 
continuous minutes while receiving oxygen therapy at 2L/min); 
and 
(b) PaCO2 of 50-54 mmHg and hospitalization related to recurrent 
(≥2 in a 12-month period) episode of hypercapnic respiratory 
failure. 
 
 
ROLE OF VACCINATIONS81-82 
 Two vaccines are recommended 
 Influenza vaccine 
 Pneumococcal vaccine 
These two vaccines are much beneficial in stage 3 and stage 4 COPD 
Patients or Patients with recurrent exacerbations. 
PHARMACOLOGICAL MANAGEMENT OF COPD 83 
FIG 27: GOLD THERAPY AT EACH STAGE OF COPD 
 
 
 
 
FIG 28: PHARMACOLOGIC TREATMENT OPTIONS  
IN COPD 
 
FIG 29: COPD INHALED PHARMACOTHERAPY 
  
 
 
INDIAN STRATEGY FOR THE MANAGEMENT OF COPD 
SUGGESTED TREATMENT GUIDELINES FOR PATIENTS  
WITH STABLE COPD  
 
 
 
 
Indications for hospital assessment or admission for exacerbations of 
COPD 
 Marked increase in intensity of symptoms, such as sudden 
development of resting dyspnea, change in vital signs 
 Severe underlying COPD 
 Onset of new physical signs (e.g. cyanosis, peripheral edema) 
 Failure of exacerbation to respond to intial medical management 
 Significant comorbidities 
 Frequent exacerbations 
 
 
 
 Newly occurring arrhythmias 
 Diagnostic uncertainty 
 Older age 
 Insufficient home support 
Indications for intensive care unit admission of patients with 
exacerbations of COPD 
 Severe dyspnea that responds inadequately to initial emergency 
therapy 
 Changes in mental status (confusion, lethargy, coma) 
 Persistent or worsening hypoxemia (Pao2 <5.3 kPa, 40mm Hg), 
and/or severe/worsening hypercapnia (Paco2 >8.0 kPa, 60mm Hg, 
and/or severe/worsening respiratory acidosis (pH < 7.25) despite 
supplemental oxygen and noninvasive ventilation. 
 Need for invasive mechanical ventilation 
 Hemodynamic instability-need for vasopressors 
 Local resources need to be considered. 
  
 
 
 
Management of severe but not life-threatening exacerbations of COPD 
in the emergency department or the hospital 
 Assess severity of symptoms, blood gases, chest X-ray 
 Administer controlled oxygen therapy and repeat arterial blood gas 
measurement after 30-60 min  
 Bronchodilators: 
- Increase doses and/or frequency 
- Combine2-agonists and anticholinergics 
- Use spacers or air-driven nebulizers 
- Consider adding intravenous methylxanthines, if needed 
 Add oral or intravenous glucocorticosteroids 
 Consider noninvasive mechanical ventilation 
 At all times: 
- Monitor fluid balance and nutrition 
- Consider subcutaneous heparin 
- Identify and treat associated conditions (e.g., heart failure, 
arthythmias) 
- Closely monitor condition of the patient. 
  
 
 
World COPD Day takes place each year on the second or third 
Wednesday in November World COPD Day 2013 theme  
“It’s Not Too Late” 
This positive message was chosen to emphasize the meaningful actions 
people can take to improve their respiratory health, at any stage before 
or after a COPD diagnosis 
 
WORLD COPD DAY 2014 LOGO 
 
FIG 30: WORLD COPD DAY-2014 LOGO 
 
 
 
 
 
 
MATERIALS AND METHODS 
SOURCE OF DATA 
 
All patients who presented with history of cough, sputum, 
breathlessness or wheezing of more than 3 months duration to the Medical 
Outpatient Department or admitted in the medical wards of Coimbatore 
Medical College Hospital were subjected to pre and post-bronchodilator 
Pulmonary Function Testing. Those patients whose post-bronchodilator 
FEV1/FVC was less than 0.7 were included in this study. This study period 
was from   AUGUST 2013 to JULY 2014. 
 
COLLABORATING DEPARTMENTS 
Department of TB & Chest Medicine, Coimbatore Medical College 
Hospital.   
 
Design of Study                       : Observational Clinical study 
Period                                         : AUGUST 2013 to JULY 2014 
Sample size                                : 60 Patients 
Ethical Committee Approval    : Obtained 
Consent                                      : Informed consent was obtained 
 
 
 
 
 
INCLUSION CRITERIA  
 Both in-patients and out-patients were included in the study. 
 Both new and previously diagnosed cases were included in the 
study.  
 Patients with post-bronchodilator FEV1 / FVC < 0.7. 
 
EXCLUSION CRITERIA 
 Patients with systemic illness like Diabetes, Coronary artery heart 
disease, Cardiac failure, renal failure, Liver diseases, Malignancy, 
Collagen vascular disease. 
 Patients with history of present or past pulmonary tuberculosis  
 Patients with other lung diseases like interstitial lung disease, 
Bronchiectasis, Pneumonia, Lung abscess. 
 Data was collected using a pretested   Proforma meeting the 
objectives of the study. Detailed history, physical examination and 
necessary investigations were undertaken.  
 Pulmonary Function Testing was done using spirometer. Three 
satisfactory efforts were recorded and the best effort was 
considered. Bronchodilatation was done using 200 μg of inhaled 
salbutamol using a metered dose inhaler and the test was repeated 
after 15 min. 
  
 
 
Patients were subjected to the following investigations: 
 Complete Haemogram 
 Peripheral smear 
 Blood urea, serum creatinine 
 Blood sugar 
 Spirometry (pre and post bronchodilator therapy) 
 Sputum for gram stain and AFB 
 Chest X-ray PA view 
 Urine: Albumin, Sugar 
 ECG in all leads  
 
 
 
 
                                  
 
 
 
 
 
 
 
RESULTS 
 
Sixty cases were studied and the following observation and analysis were 
made. 
 
TABLE 1: SEX DISTRIBUTION 
 
SEX 
NUMBER OF 
PATIENTS 
 
PERCENT 
Male 
 
48 80 
Female 
 
12 20 
Total 
 
60 100 
 
                                     CHART 1: SEX DISTRIBUTION 
 
Out of the 60 cases studied, 48 Patients  (80%) were Males and 12 
Patients  (20%)were Females. 
 
  
 
 
TABLE 2: AGE DISTRIBUTION 
 
AGE GROUP 
 
NUMBER OF 
PATIENTS 
 
PERCENT 
31 to 40 yrs 1 2 
41 to 50 yrs 28 47 
51 to 60 yrs 21 35 
61 to 70 yrs 10 17 
 
       CHART 2: AGE DISTRIBUTION 
 
 
 
Majority of the patients were in the age group of   41-50 years. 
Minimum age being  38 years and Maximum age being 68 years. 
 
 
 
 
  
 
 
TABLE 3.DURATION OF ILLNESS 
 
DURATION OF 
ILLNESS 
 
NUMBER OF 
PATIENTS 
PERCENT 
0-5  yrs 17 28 
6 to 10  yrs 28 47 
> 10  yrs 15 25 
 
 
 
                               CHART 3. DURATION OF ILLNESS 
 
 
 
Majority of patients, i.e. 28 patients (47 %)  had  duration  of  illness              
6-10 years, 15  patients  (25%)  had duration of  illness of   >10 years  
and  17 patients (28%) had duration  of  illness  0-5 years. 
 
      
 
 
TABLE:4 PLACE OF LIVING 
 
PLACE OF 
LIVING 
NUMBER  OF      
PATIENTS 
PERCENT 
Urban 48 80 
Rural 12 20 
 
 
               CHART: 4 PLACE OF LIVING
 
48  Patients (80%) were living in urban  areas whereas 12 Patients (20%) 
were  living in rural  area. 
 
  
 
 
 
TABLE: 5 BODY MASS INDEX 
BODY MASS INDEX 
 
NUMBER   OF 
PATIENTS 
PERCENT 
< 18 15 25 
18  to 23 36 60 
23 to 24.9 6 10 
> 25 3 5 
 
CHART: 5 BODY MASS INDEX 
 
 
Majority  of  Patients  (36%)  had  BMI within normal limits  (18-23kg 
/sqcm). 
 
 
 
 
TABLE 6:  SMOKING HABITS AMONG THE PATIENTS 
STUDIED 
 
SMOKING 
 
NUMBER  OF 
PATIENTS 
 
PERCENT 
Yes 34 57 
No 26 43 
   
 
CHART 6: SMOKING HABITS AMONG THE PATIENTS 
STUDIED 
 
 
Out of 60 patients, 34 patients (57%) had history of smoking. 
 
 
 
 
 
 
 
 
 
 
TABLE 7: SMOKING PACK YEARS 
 
 
PACK YEARS 
NUMBER   OF 
PATIENTS 
 
PERCENT 
NIL 
 
26 43 
20 TO 30 
 
6 10 
31 TO 40 
 
18 30 
41 TO 50 
 
6 10 
51 TO 60 
 
4 7 
 
 
 
CHART 7: SMOKING PACK YEARS 
 
 
In the present study duration of smoking ranged from 20  to 60 
Pack years. 
Majority had 31-40 pack years of duration of exposure. 
 
 
 
 
 
 
 
TABLE 8: OCCUPATIONAL EXPOSURE – COTTON MILL 
WORKERS 
 
COTTON 
MILL WORKER 
NUMBER   OF 
PATIENTS 
 
PERCENT 
Yes 35 58 
No 
 
25 42 
 
 
CHART 8: OCCUPATIONAL EXPOSURE – COTTON MILL 
WORKERS 
 
 
 
 
 
Out of 60 patients, only 35 patients (58%) had history of occupational 
Exposure. 10 patients had history of exposure for <10 years and 25 patients   
had history of exposure for >10 years. 
 
  
 
 
TABLE 9: ENVIRONMENTAL TOBACCO  SMOKE  EXPOSURE 
 
 
ETS 
 
NUMBER OF 
PATIENTS 
 
PERCENT 
YES 23 38 
NO 
 
37 62 
 
 
 
 
FIGURE 9: ENVIRONMENTAL TOBACCO SMOKE EXPOSURE 
 
 
 
History of exposure to environmental tobacco smoke was present in 23 
patients. Most of the patients, i.e. 20 patients had history of environmental 
tobacco smoke exposure for >3 hours, only 3 patients had history of 
exposure for <3 hours in a day. 
 
 
 
 
  
 
 
TABLE 10:  BIO MASS FUEL EXPOSURE 
 
 
BIO MASS FUEL 
EXPOSURE 
 
NUMBER  OF 
PATIENTS 
 
 
PERCENT 
YES 7 12 
NO 53 88 
 
 
 
 
CHART 10:  BIO MASS FUEL EXPOSURE 
 
 
 
Out of 60 patients, 7 female patients had history of biomass fuel usage and 
exposure whereas all 48 male patients (80%) did not have biomass fuel 
exposure. 
 
 
 
 
 
  
 
 
TABLE : 11 PRESENTATION OF SYMPTOMS 
 
SYMPTOMS NUMBER OF 
PATIENTS 
PERCENTAGE 
Cough 
Expectoration 
Dyspnoea 
Wheeze  
Fever 
Fatigue 
Weight Loss 
60 
60 
38 
17 
22 
13 
23 
100 
100 
63 
28 
36 
22 
38 
 
 
 
CHART 11: PRESENTATION OF SYMPTOMS 
 
 
 
Cough and Expectoration was present in all the 60 patients (100%). 
Wheeze in 38 patients (63%) and Weight loss in 23 patients (38%). 
                        
  
 
 
TABLE 12: SIGNS ON PHYSICAL EXAMINATION 
 
SIGNS NUMBER OF  
PATIENTS 
PERCENTAGE 
Tachypnoea 
Cyanosis 
Clubbing 
Accessory muscle 
Pedel edema 
JVP 
Loud p2 
Parasternal heave 
Hepatomegaly 
Crepitations 
Rhonchi 
42 
25 
9 
30 
14 
13 
12 
4 
3 
42 
42 
70 
42 
15 
50 
23 
22 
20 
7 
5 
70 
70 
 
CHART 12 :SIGNS ON PHYSICAL EXAMINATION 
 
 
 
 
Tachypnea , Rhonchi, Crepitations  were  present in 42 patients  (70%). 
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TABLE 13: CHEST EXPANSION MEASUREMENT 
  
CHEST 
EXPANSION 
NUMBER OF 
PATIENTS 
PERCENT 
> 5CM 14 23 
3 TO 5 CM 34 57 
<3CM 
 
12 20 
 
 
 
FIGURE 13: CHEST EXPANSION MEASUREMENT 
 
 
 
 
Out of 60 patients ,14 patients (23%)  had  normal  chest wall expansion 
and 46 patients  (77%) had reduced chest wall movements. 
 
 
 
  
 
 
 
TABLE 14: m MRC GRADING 
 
m MRC GRADING NUMBER  OF 
PATIENTS 
PERCENT 
1 8 13 
2 25 42 
3 19 32 
4 8 13 
 
 
 
                      CHART 14: m MRC GRADING 
 
 
 
 
25 patients had Grade 2 Dyspnoea,19 patients had Grade 3 Dyspnoea, 
8 patients had Grade 1 Dyspnoea and 8 patients had Grade 4 
Dyspnoea. 
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TABLE 15:FEV1 OF THE PATIENTS STUDIED 
 
FEV 1 NUMBER   OF                   
PATIENTS 
Mean 
Mild 21 1.82 
Moderate 23 1.24 
Severe 9 0.99 
Very Severe 7 0.54 
 
 
 
CHART 15: FEV1 OF THE PATIENTS STUDIED 
 
 
 
Post bronchodilator FEV1 results shows that  21 patients  (35%) had 
mild disease  with mean value of 1.83, 23 patients  (38%) had 
moderate disease with mean value of 1.25, 9 patients  (15%) had 
severe disease with mean value of  1.00  and 7 patients  (11%) had 
very severe disease with mean value of 0.54. 
 
 
 
 
 
 
 
 
TABLE 16: GOLD SEVERITY OF COPD 
 
GOLD 
SEVERITY OF 
COPD 
NUMBER OF 
PATIENTS 
 
PERCENT 
Mild 21 35 
Moderate 23 38 
Severe 9 15 
Very severe 7 11 
 
 
 
CHART 16:  GOLD SEVERITY OF COPD 
 
 
 
Post bronchodilator FEV1 results shows that  21 patients (35%)  had 
mild disease, 23 patients (38%) had moderate disease, 9 patients 
(15%) had severe disease and  7 patient (11%) had very severe disease 
. 
 
 
 
 
 
 
 
 
 
Table 17: CHEST X RAY OF THE PATIENTS STUDIED 
 
 
CHEST X RAY 
 
NUMBER  OF 
PATIENTS 
PERCENT 
NORMAL 5 8 
BRONCHITIS 15 25 
EMPHYSEMA 24 40 
EMPHYSEMA 
+ BRONCHITIS 
16 27 
 
 
CHART 17: CHEST X RAY OF THE PATIENTS STUDIED 
 
 
 
 
 
Chest X-ray showed Chronic bronchitis in 15 Patients, Chronic bronchitis 
with Emphysema in 16 Patients, Emphysema in 24 Patients and was 
Normal in 5 Patients. 
  
 
 
 
CHART 18: PERIPHERAL SMEAR OF THE PATIENTS 
STUDIED 
 
 
 
Peripheral smear was Normal in 28 patients, 24 patients had Normocytic 
Normochromic Anemia and 8 patients had Microcytic Hypochromic 
Anemia. 
 
 
 
 
 
Table 18: PERIPHERAL SMEAR  OF THE PATIENTS 
STUDIED 
 
PERIPHERAL 
SMEAR 
NUMBER  OF 
PATIENTS 
 
PERCENT 
NORMAL 28 47 
NORMOCYTIC 
NORMO CHROMIC 
24 40 
MICROCYTIC HYPO 
CHROMIC 
8 13 
 
 
 
 
 
 
 
Table 19:  HAEMOGLOBIN OF THE PATIENTS STUDIED 
 
 
GOLD CRITERIA 
STAGING 
NUMBER OF 
PATIENTS 
MEAN HB gm% 
Mild 21 12.8 
Moderate 23 11.4 
Severe 9 10.3 
Very severe 7 9 
 
 
 
 
CHART 19:  HAEMOGLOBIN OF THE PATIENTS STUDIED 
 
 
 
 
 
21 Patients with mild disease had Mean Haemoglobin value of 12.8, 
Moderate disease had 11.4, Severe disease had 10.3 and Very severe 
disease had value of 9. 
 
 
 
 
 
 
 
 
 
 
 
TABLE 20: MEAN CORPUSCULAR VOLUME OF THE 
PATIENTS STUDIED 
 
GOLD CRITERIA 
STAGING 
NUMBER OF 
PATIENTS 
MEAN MCV 
Mild 21 84.9 
Moderate 23 87.1 
Severe 9 88.8 
Very severe 7 88.9 
 
 
 
CHART 20: MEAN CORPUSCULAR VOLUME OF THE 
PATIENTS STUDIED 
 
 
 
 
21 Patients in mild disease had Mean MCV value of 84.9, Moderate disease 
had 87.1, Severe disease had 88.8 and Very severe disease had value of 
88.9. 
 
 
 
 
 
 
TABLE 21: MEAN CORPUSCULAR HAEMOGLOBIN OF THE 
PATIENTS STUDIED 
GOLD CRITERIA 
STAGING 
NUMBER OF 
PATIENTS 
MEAN  MCH 
Mild 21 29.1 
Moderate 23 29.4 
Severe 9 29.5 
Very severe 7 29.1 
 
 
 
 
CHART 21: MEAN CORPUSCULAR HAEMOGLOBIN OF THE 
PATIENTS STUDIED 
 
 
 
 
  
21 Patients in  mild  disease had Mean MCH value of 29.1, Moderate 
disease  had 29.4, Severe disease  had 29.5, Very severe disease  had 
29.1. 
 
 
 
 
 
 
 
 
 
TABLE 22: MEAN CORPUSCULAR HAEMOGLOBIN 
CONCENTRATION OF THE PATIENTS STUDIED 
GOLD CRITERIA 
STAGING 
NUMBER OF 
PATIENTS 
MEAN  MCHC 
Mild 21 33 
Moderate 23 32.9 
Severe 9 32.6 
Very severe 7 33.6 
 
 
 
 
FIGURE 22: MEAN CORPUSCULAR HAEMOGLOBIN 
CONCENTRATION OF THE PATIENTS STUDIED 
 
 
 
21 Patients in Mild disease had Mean MCHC value of 33, Moderate disease 
had 32.9, severe disease had 32.6, and Very severe disease had 33.6. 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 23: HAEMATOCRIT OF THE PATIENTS STUDIED 
 
GOLD CRITERIA 
STAGING 
NUMBER OF 
PATIENTS 
MEAN  HCT 
Mild 21 42.3 
Moderate 23 43.5 
Severe 9 44.2 
Very severe 7 43.7 
 
 
 
 
CHART 23: HAEMATOCRIT OF THE PATIENTS STUDIED 
 
 
 
 
21 Patients in mild disease had Haematocrit value of 42.3, Moderate 
disease had 43.5, Severe disease had 44.2, Very severe disease had 43.7. 
 
 
 
 
 
 
 
TABLE 24: COMPARISON OF AGE vs HAEMOGLOBIN 
 
AGE 
HAEMOGLOBIN 
ANEMIA NORMAL 
31 to 40 yrs 0 1 
41 to 50 yrs 19 9 
51 to 60 yrs 15 6 
61 to 70 yrs 7 3 
 
CHART 24 :COMPARISON OF AGE vs HAEMOGLOBIN 
 
Haemoglobin  of the patient were  compared with  age of the patient. 
Patient with age group ranged from 41-50 yrs  had 68% chance for 
development of anemia. . Patient with age group ranged from 51-60 yrs 
had 71% chance for development of anemia. Patient with age group ranged 
from 61-70 yrs  had 70% chance for development of anemia. 
                            
 
 
TABLE 25: COMPARISON OF AGE vs MCV 
 
AGE 
MCV 
NORMOCYTIC MICROCYTIC 
31 to 40 yrs 0 1 
41 to 50 yrs 18 10 
51 to 60 yrs 20 1 
61 to 70 yrs 8 2 
 
CHART 25: COMPARISON OF AGE vs MCV 
 
MCV  of the patient was compared with age of the patient. Patient with age 
group ranged from 41-50 yrs  had 64% chance for development of  
Normocytic Anemia. Patient with age group ranged from 51-60 yrs  had 
95% chance for development of Normocytic Anemia. Patient with age 
group ranged from 61-70 yrs  had 80% chance for development of  
Normocytic Anemia. 
This association was  statistically significant with P value of 0.020. 
 
 
TABLE 26:  COMPARISION OF AGE vs MCH 
 
AGE 
MCH 
NORMOCHROMIC HYPOCHROMIC 
31 to 40 yrs 1 0 
41 to 50 yrs 21 7 
51 to 60 yrs 19 2 
61 to 70 yrs 9 1 
 
CHART 26: COMPARISION OF AGE vs MCH 
 
MCH  of the patient was compared with age of the patient. Patient with age 
group ranged from 41-50 yrs  had 75% chance for development of  
Normochromic. Patient with age group ranged from  51-60 yrs  had  90% 
chance for development of  Normochromia. Patient with age group ranged 
from  61-70 yrs  had  90% chance for development of  Normochromia. 
This association was not statistically significant with P value of 0.442. 
 
 
 
TABLE 27: COMPARISON OF  SEX vs HAEMOGLOBIN 
 
SEX 
 
HAEMOGLOBIN 
ANAEMIA NORMAL 
MALE 32 16 
FEMALE 9 3 
 
FIGURE 27: COMPARISON OF  SEX vs HAEMOGLOBIN 
 
 
Haemoglobin  of the patient was compared with age of the patient. Among 
48 male patients 32 (67%) had anemia. Among 12 female patients 9 (75%) 
had anemia. 
 
 
 
 
 
 
TABLE 28 : COMPARISON OF  SEX vs MCV 
 
SEX 
 
MCV 
NORMOCYTIC MICROCYTIC 
MALE 38 10 
FEMALE 8 4 
 
CHART 28: COMPARISON OF  SEX vs MCV 
 
MCV  of the patient was compared with age of the patient. Among 48 
male patients 38 (79%) had normocytic. Among 12 female patients 8                
(67%) had normocytic. 
 
 
 
 
 
 
 
TABLE 29: COMPARISON OF  SEX vs MCH 
 
SEX 
 
MCH 
NORMOCHROMIC HYPOCHROMIC 
MALE 42 6 
FEMALE 8 4 
 
CHART 29 : COMPARISON OF  SEX vs MCH 
 
MCH  of the patient was compared with age of the patient. Among 48 male 
patients 42 ( 88%) had  normochromic. Among 12 female patients 8 ( 67%) 
had normochromic. 
 
 
 
 
 
 
TABLE 30: DURATION OF ILLNESS vs HAEMOGLOBIN 
DURATION OF 
ILLNESS 
 
HAEMOGLOBIN 
ANEMIA NORMAL 
0-5 yrs 12 5 
6 -10 yrs 16 12 
>10 yrs 13 2 
 
FIGURE 30: DURATION OF ILLNESS vs HAEMOGLOBIN 
 
Haemoglobin of the patient was compared with Duration of illness. 
Patient with duration of illness more than 6-10yrs had 57% risk for anemia 
and duration of illness more than 10 yrs had 87% risk for anemia. 
 
 
 
 
TABLE 31: COMPARISON OF SMOKING WITH 
HAEMOGLOBIN 
 
SMOKING 
 
HAEMOGLOBIN 
ANAEMIA NORMAL 
YES 25 9 
NO 16 10 
 
CHART 31: COMPARISON OF SMOKING WITH 
HAEMOGLOBIN 
 
 
Haemoglobin  of the patient was compared with Smoking. 
Among the patients with smoking 73% had anemia and in non-smokers  
61% had anemia. Although this association was considerable but it was not 
statistically significant with  P value of 0.322 
 
 
 
TABLE 32: COMPARISON OF OCCUPATIONAL EXPOSURE –
COTTON MILL WORKERS WITH HAEMOGLOBIN 
COTTON 
MILL WORKER 
 
HAEMOGLOBIN 
ANAEMIA NORMAL 
YES 25 10 
NO 16 9 
 
CHART 32: COMPARISON OF OCCUPATIONAL EXPOSURE –
COTTON MILL WORKERS WITH HAEMOGLOBIN 
 
 
Haemoglobin  of the patient was compared with Mill workers.Among the 
mill workers  71% had anaemia and 64% in non –mill workers. Although 
this association was considerable but it was not statistically significant. 
 
 
 
 
TABLE 33: m MRC GRADING vs HAEMOGLOBIN 
m  MRC 
GRADING 
 
HAEMOGLOBIN 
ANEMIC NORMAL 
1 6 2 
2 19 6 
3 17 2 
4 8 0 
 
CHART 33: m MRC GRADING vs HAEMOGLOBIN 
 
Haemoglobin of the patient was compared with m  MRC GRADING. 
Patients with increased Grades of Dyspnea had more risk for anemia and 
vice versa. 
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DISCUSSION 
 
This clinical observational study was undertaken to investigate the 
pattern and magnitude of Hematological parameters in the relationship 
with the Severity of the disease. The study consisted of 60 subjects, among 
them   21 Patients had mild COPD, 23 Patients with moderate COPD, 9 
Patients had severe COPD and 7 Patients had very severe COPD. 
 
All the individuals in different groups were subjected to detailed 
History and Physical examination. Lung function parameters were 
assessed with the help of spirometer. All patients underwent 
Haematological parameters with particular reference to Hb%, MCV, 
MCH, MCHC, HAEMATOCRIT, PERIPHERAL SMEAR along with 
routine tests. 
The aim of the present study was to assess the relationship between   
Physical examination, Hematological parameters and the severity of 
COPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. COMPARISON OF AGE DISTRIBUTION  WITH OTHER 
STUDIES 
 
STUDIES MEAN AGE 
Behrendt et al. 42.2 
Kamat SR et al 50 
Our study 44 
 
The mean age of present study population was 44 years which was 
comparable to Behrendt et al. study. 
 
2. COMPARISON OF SEX DISTRIBUTION WITH OTHER 
STUDIES 
STUDIES MALE FEMALE 
Behrendt et al. 30.83% 69.17% 
Mahesh et al. 11.54% 88.46% 
Kamat SR et al 88.8% 11.2% 
Our study 80% 20% 
 
In the our study, males account for 80%, and females account for 20% 
with a Male : Female ratio of 4:1 
 
 
 
 
 
3. COMPARISON OF PLACE OF LIVING WITH OTHER 
STUDIES 
STUDIES URBAN RURAL 
Celli B et al. 58.80% 46.20% 
Goel S et al. 27.27% 72.73% 
Our study 80% 20% 
 
In our study 80% patients were from Urban area . 
                                        
                                       
 
4. COMPARISON OF  DURATION OF ILLNESS WITH OTHER 
STUDIES 
 
DURATION 
OF 
ILLNESS 
Thiruvengadam 
KV 
(N=30) 
Kamat  SR 
(N=50) 
OUR STUDY 
(N=60) 
0- 5 yrs 33.3 40 28 
6-10 yrs 43.3 40 47 
>10 yrs 23.3 20 25 
. 
The duration of illness in all the study group showed more patients 
belonging to  6-10 years of duration. 
            
 
 
 
 
5. PREVALENCE OF SMOKERS AND NONSMOKERS 
STUDIES SMOKERS NON SMOKERS 
Thiruvengadam 
KV et al. 
 
87% 13% 
OUR STUDY 57% 43% 
 
Smoking is being very important risk factor for COPD seen in most of the 
patients who develop COPD. In the present study 71% males were 
smokers, when compared with the Thiruvengadam KV et al. study group, 
who also had smoking history in all males. Among the smokers 73% had 
anemia and in Non- smokers 61% had anemia. Although this association 
was considerable but it was not statistically significant with P value of 
0.322 
6. COMPARISON OF SYMPTOMS WITH OTHER STUDIES 
SYMPTOMS Behrendt  et al Mahesh et al Our study 
COUGH 11.55% 100% 100% 
EXPECTORATION 7.05% 100% 100% 
WHEEZE 25.57% 90.9% 63% 
 
In our study, cough and expectoration were predominant symptoms, 
Followed by wheeze. Symptom profile is comparable with Mahesh et al. 
study. 
   
 
 
 
 
7. COMPARISON OF FEV1 WITH HAEMOGLOBIN 
 
 
There is significant positive correlation between FEV1 and 
Haemoglobin with r=0.322 at  P = 0.12 < 0.05 Level. 
  
 
 
8. Among the patients studied 58% had exposure to cotton mill 
industry.Among them 71% had anemia. 
 
9. Patient with increased levels of Dyspnea (m MRC Grading) had 
more risk for anemia 
         Grade 2 Dyspnea - 76%  had anemia 
         Grade 3 Dyspnea – 89%  had anemia 
         Grade 4 Dyspnea -  100%  had anemia. 
                                            
  
 
 
CONCLUSION 
1. The age of the patients being studied ranged between 30 yrs to 70 yrs 
and the majority of the patients were in the age group of   41-50 years. 
2. In our study, out of 60 patients  48 (80%) were males and 12 (20%)  
were females. The Male:Female ratio of this study was 4:1. 
3. In our study, the duration of illness was more in patients with severe 
COPD as compared to the mild and moderate COPD group. This shows 
that the severity of COPD increases with the duration of illness. 
4. In our study Post bronchodilator FEV1 results showed that 21 patients 
(35%) had GOLD CRITERIA of mild disease who had a mean of 1.82, 
23 patients (38%) had moderate disease who had a mean of 1.24,                     
9 patients (15%) had severe disease who had a mean of 0.99 and                                           
7 patient (11%) had very severe disease who had a mean of 0.54. 
5. The most common symptoms were  cough and expectoration , Present 
in all the 60 patients (100%). The most common sign observed was 
tachypnea in 42 (70%) patients. 
6. In our study out of 60 (100%) patients studied chest x ray shows 
Chronic bronchitis in 15 patients , Chronic bronchitis with  Emphysema 
in 16 patients , Emphysema in 24 patients and was Normal in 5 patients  
7. Among the Patients 57%  were smokers. 71% of male patients had a 
history of smoking for 5yrs or more. Among smokers 73% had anemia 
and in Non-smokers 61% had anemia. 
 
 
8. In our study 56% of Patients had anemia.Among them 70% had 
Normocytic Normochromic Anemia and the remaining 30% had  
Microcytic Hypochromic Anemia. 
9. The Prevalence of  anemia  was  more common with increased duration 
of illness.Duration of illness 6-10 yrs had 57% risk for anemia and > 10 
yrs  had 87%  risk of  anemia. 
10. The prevalence of  anemia was more common in  Cottton mill workers   
with 71% and 64% in non –mill workers. 
11. The prevalence of anemia was more common in Patients with m MRC  
grade 3 and 4 dyspnoea. 
12. In our study the fall in FEV1 was associated with fall in Haemoglobin 
percentage and vice versa. 
                                 
 
 
 
 
 
 
                             
 
 
SUMMARY 
 
This study was conducted to detect the haematological 
manifestations in relation to FEVI in COPD Patients.60 Patients were 
included in this study. 
Results from the study showed Patients with decreased FEV1, 
having prolonged duration of illness and increasing grades of dyspnea had 
high risk for anemia. Patients with exposure to Cotton Mill dust and with 
the history of smoking had increased risk for anemia, but its association 
was not statistically significant. 
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PROFORMA 
NAME OF THE PATIENT: 
AGE:                                          SEX: 
OCCUPATION:  
ADDRESS: 
EDUCATION: 
MARITAL STATUS: 
INCOME: 
DATE OF ADMISSION: 
DATE OF EXAMINATION: 
IP NUMBER:                                                   OP NUMBER: 
 PRESENTING COMPLAINTS:                   DURATION                                                   
1. Cough 
2. Breathlessness 
3. Sputum 
4. Hemoptysis  
5. Weight loss 
6. Weakness and fatigue 
9. Wheeze 
10. Fever 
11. Chest pain 
12. Swelling of lower limbs 
 
 
A) HISTORY OF PRESENTING COMPLAINTS: 
1. Cough : 
     Duration 
     Dry/productive 
     Persistent/paroxysmal 
    Postural variation- Present/Absent 
    Diurnal variation - Present/Absent 
    Seasonal variation- Present/Absent 
    Progression- Increasing/decreasing/persisting 
    Any triggering factors- Smoke/cold/pollen/infection/dust 
    Relation to occupation- Increased at work/not 
2. Breathlessness : 
    Duration 
    Onset- Sudden/insidious 
    Progression- increasing/deteriorating/static 
    Persistent/paroxysmal 
    Relation to exertion- present/absent 
    Seasonal variation- present/absent 
    Precipitating factors- present/absent 
    Any triggering factors- Smoke/cold/pollen/infection/dust 
    Orthopnoea/trepopnoea/platypnoea/PND 
 
 
 
3. Sputum: 
Colour 
Quantity minimal/ moderate/ copious 
Consistency 
Postural variation Yes/ No 
Diurnal variation Yes/ No 
Foul smell-present/absent 
 
4. Weight loss: Percentage of loss of weight: 
Time period: 
 
5. Chest pain : 
 Duration 
 Onset- Sudden/insidious 
 Location. 
 Nature of pain- pleuritic/anginal/other types 
 Radiationf. 
 Aggravating factors- deep inspiration/exertion/cough/any other 
 Relieving factors. 
 Duration of each episode  
 
 
 
 
6. Wheezing : 
 Duration. 
 Precipitating factors. 
 Duration of attack 
 Seasonal variation- Present/Absent 
 
7. Hemoptysis: Present/Absent 
  If present- Streaky/frank hemoptysis/pink frothy 
 
8. Fever : 
  Onset- sudden/insidious 
  Type- continuous /intermittent/remittent 
  Accompanied by chills / rigors / sweating 
 
9. Swelling of lower limbs: 
  Onset- sudden/insidious 
  Duration. 
  Pain- present/absent 
  Diurnal variation- present/absent 
  Postural variation- present/absent 
 
 
 
 
10. Any other symptoms; Details: 
B) Past history: 
History of similar complaints 
H/O tuberculosis/ asthma/ /allergy/epilepsy/nasal polyps/sinusitis/cardiac 
illness/ diabetes mellitus/hypertension/ repeated respiratory infections 
in childhood 
History of exacerbations: 
Number of exacerbations: 
Hospitalization was required or not: Yes/ No 
Duration of hospitalization: 
 
C) Family history: 
History of Asthma/tuberculosis/allergic disease. 
No. of family members smoking. 
Exposure to smoke (passive smoking) during infancy and childhood. 
 
D) Personal history: 
Diet: veg/ nonveg/ mixed 
Sleep: Sound/ disturbed 
Snoring- present/absent 
Early morning headache- present/ absent 
Appetite: Normal/decreased/increased 
Bowel habits: regular habits/ constipated/loose stools 
 
 
Habits: 
Smoking: Yes/No 
ETS or Passive Smoking exposure: Yes/ No 
If Yes: 
At Home/ work place 
Duration of exposure: <3hrs/ >3hrs per day 
Years of exposure: 
 
Exposure to bio mass fuels at home or work place: yes/no 
Duration of exposure: nature of fuel: 
No. of years exposure: 
Tobacco chewing: No. of times/day- 
Duration 
Snuff inhalation: yes/no 
Alcohol: Quantity- 
Duration- Type- 
 
Occupational exposure to dust/fumes/vapors/smoke/chemicals. 
Nature of exposure 
Duration of exposure per day: hours per week 
Place of living: urban/ rural 
 
 
 
Exposure to atmospheric air pollution: present/ absent 
E) Menstrual history: regular/irregular. 
F) Treatment history: h/o taking any steroids, any beta 2 agonist or any 
theophylline derivative. 
2. A) GENERAL PHYSICAL EXAMINATION: 
    Comfortable/dyspnoeic 
    Built: well built/moderate built/poorly built 
    Nourishment: well nourished/moderate/poorly 
   Weight: 
   Height: 
   Body mass index: 
   B) Vital signs 
   Pulse: 
   Rate- / min 
   Rhythm- 
   Volume- 
   Condition of the Vessel wall: 
     Blood Pressure:         mm/Hg 
   Respiration: Rate- 
   Rhythm 
   Type 
   Temperature: °C 
 
 
   Pallor: Present/absent 
   Cyanosis: Present/absent 
   Central/ peripheral/mixed 
   Clubbing: present/absent degree 
   Koilonychia/platynychia: Present/absent 
   Icterus: Present/absent 
   Lymphadenopathy: Present/absent 
   Oedema: Present/absent 
   Any other significant signs- 
3. SYSTEMIC EXAMINATION: 
RESPIRATORY SYSTEM 
A) Upper respiratory system: 
B) Lower respiratory tract 
INSPECTION: 
a. Position of the trachea: Central / left / right. 
b. Shape of the chest: Normal/ barrel chest/ pigeon chest/ pectus 
excavatum / kyphoscoliosis / Harrison’s sulcus /any other chest 
deformity. 
c. Asymmetry: Bulging/ retraction. 
d. Respiratory movements: Normal 
    Diminished- bilateral / unilateral / localized 
e. Respiratory sounds heard: respiratory stridor/ respiratory wheeze 
 
 
f. Position of the apical impulse: 
g.Visible veins over the chest: present/absent 
h.Special features to be noted 
i.Tracheal descent with inspiration 
j.Excessive use of scalene and sternocleidomastoid muscle 
PALPATION: 
a. Position of the trachea: central/right/left. 
b. Position of the apical impulse: 
c. Movements of the chest wall- normal / decreased 
d. Measurements: during Deep inspiration - cms 
           Deep expiration - cms 
           A P diameter - cms 
           Transverse diameter- cms 
           Chest expansion- cms 
           Hemithorax Right- cms 
           Left- cms 
e. Any palpable rhonchi or rub – 
f. Vocal fremitus- Normal / increased / decreased 
Areasg. 
Tenderness over the chest- areas 
 
  
 
 
PERCUSSION: 
a. Percussion note: Normal / impaired / hyper resonant / woody dullness/ 
    stony dullness 
b. Liver dullness: 
c. Cardiac dullness- Normal/ obliterated. 
d. Tidal percussion - Normal / diminished 
 
AUSCULTATION: 
a. Breath sound: type: NVBS / bronchial / vesicular breath sounds with 
    prolonged expiration. 
b. Air entry: Normal / diminished / absent 
c.Rhonchi: Present / absent 
d.Crepitation: Present / absent 
   Inspiratory/expiratory 
   Fine/coarse 
e.Pleural rub: Present / absent 
f.Vocal resonance: Normal / increased /decreased 
 
  
 
 
CARDIOVASCULAR SYSTEM: 
ABDOMEN: 
NERVOUS SYSTEM: 
4. INVESTIGATION 
BLOOD: Hb%- 
TC     DC 
ESR     FBS 
PPBS     Blood Urea 
Serum creatinine 
URINE: Albumin-   Sugar- 
Microscopy- 
SPUTUM: Quantity per day- 
Colour-                   Odour- 
Blood: present/ absent 
Microscopy: Gram stain 
AFB stain 
CHEST RADIOGRAPH: Report – 
SPIROMETRIC PARAMETERS: Pre bronchodilator Post bronchodilator 
FVC: 
FEV1: 
FEV1/FVC: 
 
 
 
 
 
 
STATISTICAL METHODS 
 
       The collected data was analysed with SPSS 16.0 version. To describe 
about the data descriptive statistics frequency analysis, percentage 
analysis, mean and S.D were used. To associate the various clinical 
variables Chi-Square test was done.In the above statistical tool the 
probability value .05 is considered as significant level.  
 
  
 
 
 
KEY TO MASTER CHART 
S.NO-SERIAL NUMBER 
ETS-ENVIRONMENTAL TOBACCO EXPOSURE 
BMI-BODY MASS INDEX 
JVP-JUGULAR VENOUS PULSE 
m  MRC-MODIFIED MEDICAL RESEARCH COUNCIL 
HB –HAEMOGLOBIN 
MCV-MEAN CORPUSCULAR VOLUME 
MCH-MEAN CORPUSCULAR HAEMOGLOBIN  
MCHC- MEAN CORPUSCULAR HAEMOGLOBIN 
CONCENTRATION 
SEX 
1 =  MALE 
2=  FEMALE 
 
AGE 
 1=  21-30 YRS 
2=   31- 40 YRS 
3=   41-50YRS 
4=   51-60 YRS 
 
 
 
 
PLACE OF LIVING 
1=  URBAN 
2=  RURAL 
 
BMI 
1=   < 18 kg/sqcm 
2=   18-23 kg/sqcm 
3=   23-24.9 kg/sqcm 
4=   > 25 kg/sqcm 
 
GOLD CRITERIA SEVERITY OF COPD 
1=  mild 
2=  moderate 
3=  severe 
4=  very severe 
 
SMOKING 
1=  yes 
2=  no 
 
PACK YEARS 
1=   nil 
2=   20-30 pack years 
 
 
3=   31-40 pack years 
4=   41-50 pack years 
5=   51-60 pack years 
 
MILL WORKER /ETS /BIOMASS FUEL 
1=  yes 
2=  no 
 
PRESENTING SYMPTOMS 
COUGH EXPECTORATION DYSPNOEA WHEEZE FEVER FATIGUE 
WEIGHT 
LOSS 
 
1=  yes 
2=  no 
PRESENTING SIGNS  
TACHYPNOEA CYANOSIS CLUBBING 
ACCESSARY 
MUSCLE 
PEDEL 
EDEMA 
JVP 
LOUD 
P2 
PARASTERNAL 
HEAVE 
HEPATOMEGALY CREPITATIONS RHONCHI 
 
1=  yes 
2=  no 
 
 
CHEST EXPANSION 
1=   >5cm 
2=    3-5cm 
3=   <3cm 
 
 
 m MRC  GRADING 
1= 1 
2= 2 
3=  3 
4=  4 
 
Fev1  
1 =   mild 
2=    moderate 
3=    severe 
4=   very severe 
 
Chest x ray 
1=   Normal 
2=   Bronchitis 
3=   Emphysema 
4=    Emphysema +Bronchitis 
 
 
PERIPHERAL SMEAR 
1=  Normal 
2=  Normocytic normochromic 
3=   Microcytic hypochromic 
 
 
 
 
 
S.NO NAME SEX AGE PLACE OF LIVING
DURATION 
OF ILLNESS
BMI
GOLD 
SEVERITY OF 
COPD
SMOKING
PACK 
YEARS
MILL 
WORKERS
ETS
BIOMASS 
FUEL
COUGH
EXPECTOR
ATION
DYSPNOEA WHEEZE FEVER FATIGUE
1 GANESAN 1 3 1 1 2 1 2 1 1 2 2 1 1 1 1 1 2
2 ARUMUGHAM 1 3 1 1 4 1 1 2 1 2 2 1 1 2 2 2 2
3 KARUPPAN 1 3 1 1 4 1 2 1 1 1 2 1 1 1 1 2 2
4 PAYCHI 2 3 2 2 2 1 2 1 1 2 1 1 1 2 2 2 2
5 KALIAMMA 1 2 1 2 2 1 2 1 2 1 2 1 1 1 1 2 2
6 MURUGAN 1 3 1 1 3 1 1 3 2 2 2 1 1 2 2 2 2
7 LAKSHMI 2 3 2 1 3 1 2 1 2 1 1 2 2 1 2 2 2
8 SUNDARAMORTHY 1 5 1 2 3 1 2 1 2 2 2 1 1 2 2 2 2
9 VAIRAMUTHU 1 4 1 1 2 1 1 3 2 2 2 1 1 1 1 1 2
10 KANNAN 1 4 1 1 4 1 2 1 1 1 2 1 1 1 1 2 2
11 PASUMPON 1 5 1 1 2 1 1 3 2 2 2 2 2 1 1 1 1
12 PAYCHIMUTHU 1 5 1 1 2 1 2 1 2 1 2 2 2 1 2 2 2
13 BHARATHIRAJAN 1 4 1 2 2 1 1 3 1 2 2 1 1 2 2 1 2
14 VENKATACHALAM 1 4 1 2 2 1 1 2 1 2 2 2 2 1 2 2 2
15 ARIVAZHAN 1 3 1 1 2 1 1 2 2 2 2 1 1 2 2 1 2
16 MANIYAN 1 4 1 2 2 1 2 1 2 1 2 2 2 1 2 2 1
17 MAHALI 1 5 1 1 2 1 2 1 1 2 2 1 1 1 1 2 2
18 NATARAJAN 1 3 1 2 2 1 1 3 1 1 2 1 1 1 2 1 1
19 PANDIYARAJAN 1 4 1 2 2 1 2 1 1 2 2 1 1 1 1 1 1
20 KUPPUSAMY 1 5 1 2 2 1 1 3 1 2 2 1 1 1 2 2 1
21 GUNAVATHI 2 3 2 3 2 1 2 1 2 1 2 1 1 1 2 2 1
22 ILANGO 1 3 1 3 2 2 1 2 1 2 2 2 2 1 2 2 2
23 MARIMUTHU 1 3 1 1 2 2 2 1 1 1 2 1 1 1 2 2 2
24 MURUGESAN 1 4 1 2 3 2 1 4 1 2 2 2 2 1 2 2 2
25 SIVARAJ 1 3 1 3 3 2 1 3 2 2 2 1 1 1 2 2 2
26 PARTHIBAN 1 5 1 3 3 2 2 1 2 2 2 2 2 1 2 2 2
27 SUMANGALI 2 3 2 3 2 2 1 3 2 1 2 1 1 2 2 2 2
28 THANGAVEL 1 3 1 2 2 2 1 3 2 2 2 2 2 1 2 2 2
29 VELLINGIRI 1 3 1 2 2 2 1 3 2 1 2 1 1 2 1 2 2
30 RUBAN 1 4 1 2 2 2 2 1 1 2 2 2 2 1 1 2 2
31 PADMANABAN 1 4 1 2 2 2 1 2 1 2 2 1 1 2 1 2 2
32 SUNDARAM 1 3 1 3 2 2 2 1 1 1 2 1 1 1 2 2 2
33 MUTHUCHELVI 2 3 2 2 1 2 2 1 2 1 1 1 1 2 2 2 2
34 ALAGUSMY 1 3 1 2 1 2 1 4 1 2 2 1 1 1 2 2 2
35 RANGARJ 1 3 1 2 1 2 1 5 1 2 2 2 2 1 2 2 2
36 YUSUF 1 4 1 1 1 2 1 5 1 2 2 1 1 1 2 2 2
37 SELVI 2 4 2 2 2 2 2 1 1 2 1 1 1 2 2 2 2
38 KARTHIKEYAN 1 3 1 1 1 2 1 3 2 2 2 1 1 1 1 2 2
39 THULASIMANI 2 4 2 2 2 2 2 1 2 1 1 1 1 2 2 1 2
40 SURESHBABU 1 3 1 1 2 2 1 3 1 2 2 1 1 2 2 2 2
41 CHINAMMA 2 4 2 2 2 2 2 1 2 2 1 1 1 2 2 2 2
42 KANMANI 2 3 2 1 1 2 2 1 1 1 2 1 1 2 2 1 2
43 GURUSAMY 1 4 1 2 2 2 1 5 1 2 2 2 2 1 2 1 2
44 PECHIYAMMAL 2 5 2 2 1 2 2 1 2 1 1 1 1 2 2 1 2
45 GEORGE 1 4 1 2 2 3 1 3 1 2 2 2 2 1 2 1 2
46 PAULRAJ 1 5 1 3 1 3 1 3 1 1 2 1 1 2 1 1 1
47 MANICKAM 1 3 1 3 2 3 1 5 1 2 2 2 2 1 2 1 1
48 DHIVAGARAN 1 3 1 2 2 3 1 3 1 1 2 1 1 2 2 1 1
49 CHELLADURAI 1 3 1 3 2 3 1 3 1 2 2 2 2 1 1 1 2
50 PALANI 1 3 1 3 2 3 2 1 2 2 2 2 2 1 1 2 2
51 RANGASAMY 1 4 1 3 1 3 1 4 2 1 2 1 1 2 1 2 2
52 JAYAKUMAR 1 3 1 1 1 3 1 4 2 2 2 2 2 1 1 2 1
53 SENTHILVEL 1 3 1 2 2 3 2 1 2 2 2 1 1 2 2 2 2
54 VENKATACHALAM 1 5 1 2 2 4 1 4 1 1 2 2 2 1 2 2 1
55 SHANMUGAVEL 1 5 1 2 1 4 1 4 1 1 2 1 1 2 2 1 1
56 KANNIAMMA 2 4 2 2 2 4 2 1 1 1 2 1 1 1 2 1 1
57 SUBRAMANI 1 4 1 3 1 4 1 3 2 1 2 2 2 1 2 1 2
58 VIMALA 2 4 2 3 1 4 2 1 1 2 2 1 1 2 2 1 2
59 KANAGARAJ 1 4 1 3 1 4 1 2 1 2 2 1 1 1 2 1 2
60 PARAMAN 1 4 1 3 1 4 1 3 1 2 1 1 1 2 1 2
BIO DATA RISK FACTORS PRESENTATION OF SYMPTOMS
 
 
S.NO NAME
WEIGHT 
LOSS
TACHYPNOEA CYANOSIS CLUBBING
ACCESSARY 
MUSCLE
PEDEL 
EDEMA
JVP
LOUD 
P2
PARASTERNAL 
HEAVE
HEPATO
MEGALY
CREPITA
TIONS
RHONCHI
CHEST 
EXPANSI
ON
mMRC 
GRADE
FEV1 
CHEST X-
RAY
HB % HCT MCV MCH MCHC
PERIPHERAL 
SMEAR
1 GANESAN 1 1 2 2 2 2 2 2 2 2 1 1 1 1 2 .02 2 12 .4 45.9 81 28 32 .4 1
2 ARUMUGHAM 2 1 2 2 2 2 2 2 2 2 1 1 1 3 1.98 2 13 .4 43 .5 86 28 .6 34 .4 1
3 KARUPPAN 2 1 2 2 2 2 2 2 2 2 1 1 1 3 1.66 2 12 .8 40 .6 95 30 34 .6 1
4 PAYCHI 2 1 2 2 2 2 2 2 2 2 1 1 1 2 1.6 2 14 .4 43 .6 88 31 35.4 1
5 KALIAMMA 2 2 2 2 2 2 2 2 2 2 1 1 1 1 2 2 15 42 .2 96 32 32 1
6 MURUGAN 2 1 2 2 2 2 2 2 2 2 1 1 1 1 1.7 1 8 .6 43 56 25 28 .8 3
7 LAKSHMI 2 1 2 2 2 2 2 2 2 2 1 1 1 1 1.86 2 11.2 44 67 24 .6 27.8 3
8 SUNDARAMORTHY 2 2 2 2 2 2 2 2 2 2 1 1 1 1 1.72 3 15.2 45.2 90 30 36 1
9 VAIRAMUTHU 2 2 2 2 2 2 2 2 2 2 1 2 1 1 1.66 2 16 .6 43 .6 89 31 32 .4 1
10 KANNAN 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1.8 2 11 40 .2 90 .4 29 .6 32 .8 1
11 PASUMPON 2 2 2 2 2 2 2 2 2 2 2 2 1 3 1.52 2 10 .8 40 .4 70 23 27.6 3
12 PAYCHIMUTHU 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 3 13 40 .6 89 29 .4 32 1
13 BHARATHIRAJAN 1 2 2 2 2 2 2 2 2 2 2 1 1 2 2 .02 2 12 .4 40 .8 89 30 .4 33 1
14 VENKATACHALAM 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 13 43 .4 88 30 .2 34 1
15 ARIVAZHAN 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2 1 15 43 .8 92 .4 31.8 35.4 1
16 MANIYAN 2 1 2 2 1 2 2 2 2 2 2 2 2 3 1.98 2 14 44 93 28 .8 35.6 1
17 MAHALI 2 1 2 2 1 2 2 2 2 2 1 2 2 3 1.78 3 13 40 90 .2 29 .2 35.8 1
18 NATARAJAN 2 1 2 2 2 2 2 2 2 2 1 1 2 2 1.9 1 14 40 .6 93 32 34 .2 1
19 PANDIYARAJAN 2 1 2 2 2 2 2 2 2 2 1 1 2 3 1.88 3 13 40 .7 87.4 31.6 34 .6 1
20 KUPPUSAMY 2 1 2 2 2 2 2 2 2 2 2 1 2 2 1.68 1 11.2 40 .2 82 .7 32 34 .8 2
21 GUNAVATHI 2 1 2 2 1 2 2 2 2 2 2 1 2 2 1.58 4 9 42 .4 69 22 .8 30 .2 3
22 ILANGO 2 2 2 2 1 2 2 2 2 2 2 1 1 3 0 .9 3 13 43 .8 88 .8 32 34 .8 1
23 MARIMUTHU 2 2 2 2 1 2 2 2 2 2 2 1 2 3 1.22 3 8 .6 44 .4 74 24 .2 31.2 3
24 MURUGESAN 2 2 1 2 1 2 2 2 2 2 2 1 2 2 1.34 2 12 43 .2 92 .6 31.4 32 1
25 SIVARAJ 2 2 1 2 1 2 2 2 2 2 2 1 2 2 1.22 2 16 42 .5 88 32 32 .8 1
26 PARTHIBAN 2 2 2 2 1 2 2 2 2 2 1 1 2 2 1.4 2 11.4 42 .6 90 32 32 .8 2
27 SUMANGALI 2 1 2 2 1 2 2 2 2 2 1 1 2 2 1.36 4 8 42 .8 76 .8 20 .8 28 .8 3
28 THANGAVEL 2 1 2 2 1 2 2 2 2 2 1 2 2 2 1.38 3 11.2 42 .6 80 .4 32 .4 32 .4 2
29 VELLINGIRI 2 1 2 2 2 2 2 2 2 2 1 2 2 2 1.4 4 10 44 88 32 34 .2 2
30 RUBAN 1 1 1 2 1 2 2 2 2 2 2 2 2 2 1.48 3 12 43 .6 92 .5 32 34 .8 1
31 PADMANABAN 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1.44 3 9 .8 42 .8 77 2O.4 29 .6 3
32 SUNDARAM 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1.06 3 8 42 .7 88 .5 31 36 2
33 MUTHUCHELVI 2 2 2 2 1 2 2 2 2 2 1 2 2 2 0 .94 3 6 .6 44 75 23 .8 30 3
34 ALAGUSMY 2 1 1 2 1 2 2 2 2 2 1 2 2 2 0 .88 4 14 43 .4 90 .2 28 35.4 1
35 RANGARJ 2 1 2 2 1 2 2 2 2 2 1 2 2 2 0 .98 3 13 45 91.4 32 36 .2 2
36 YUSUF 2 1 1 2 2 2 2 2 2 2 1 1 2 2 1.28 3 12 44 .2 91 32 .4 34 .6 1
37 SELVI 1 1 2 2 2 2 2 2 2 2 1 1 2 3 1.36 4 16 44 .8 93 .6 28 .8 34 .6 1
38 KARTHIKEYAN 1 1 2 2 2 2 2 2 2 2 2 1 2 2 1.34 3 9 44 .2 86 .8 28 31.8 2
39 THULASIMANI 2 2 2 2 2 2 2 2 2 2 2 1 2 3 1.12 3 15 42 .2 95 28 34 .4 1
40 SURESHBABU 2 2 2 1 2 2 2 2 2 2 1 1 2 3 1.24 3 12 .2 43 .6 87.6 29 .4 34 .2 1
41 CHINAMMA 1 1 1 1 2 2 2 2 2 2 1 1 2 2 1.28 4 10 42 .6 86 .7 30 .4 28 .8 2
42 KANMANI 1 1 2 2 1 2 2 2 1 1 1 1 2 2 1.24 4 11.4 44 .4 89 .2 32 31.8 2
43 GURUSAMY 2 1 2 2 1 2 2 1 1 1 1 1 2 2 1.48 4 12 43 90 .6 32 35 1
44 PECHIYAMMAL 1 1 1 2 1 2 2 1 1 1 1 1 2 2 1.36 4 10 .8 43 .6 89 .6 31.4 31.4 2
45 GEORGE 1 1 1 1 2 2 2 1 2 2 1 2 3 3 1.34 4 12 43 .8 89 30 .4 34 1
46 PAULRAJ 1 1 1 1 2 2 2 1 2 2 1 2 3 4 1.24 3 11 43 .3 88 .8 30 .6 31.4 2
47 MANICKAM 1 1 1 1 1 1 2 2 2 2 1 1 3 3 1.02 4 11 43 .6 88 .4 30 .8 32 2
48 DHIVAGARAN 2 1 1 1 1 1 1 2 2 2 1 1 2 3 0 .94 3 10 .8 46 .8 84 29 .8 32 2
49 CHELLADURAI 1 1 1 2 1 1 1 1 2 2 1 1 3 3 0 .92 4 7.6 45 82 .2 28 .4 32 .8 2
50 PALANI 2 1 1 2 1 1 1 1 2 2 1 1 2 4 0 .88 3 9 .8 43 .8 88 28 .4 32 .4 2
51 RANGASAMY 1 1 1 2 1 1 1 1 1 2 1 1 3 4 0 .98 4 7.8 44 .8 92 28 .8 32 .4 2
52 JAYAKUMAR 2 1 1 1 2 1 1 2 2 2 1 1 2 3 1 3 8 .6 44 .2 92 .4 28 .8 32 2
53 SENTHILVEL 1 1 1 1 1 1 1 2 2 2 1 1 3 4 0 .65 3 14 42 .4 94 29 .6 34 I
54 VENKATACHALAM 2 1 1 1 1 1 1 2 2 2 1 1 3 4 0 .66 4 9 .6 43 86 .4 29 .8 34 .4 2
55 SHANMUGAVEL 1 1 1 2 1 1 1 2 2 2 1 1 3 3 0 .58 3 11 43 .4 88 29 .4 34 .8 2
56 KANNIAMMA 1 1 1 2 1 1 1 1 2 2 1 1 3 4 0 .62 2 10 .4 45.2 86 .2 28 .4 35 2
57 SUBRAMANI 1 1 1 2 1 1 1 1 2 2 1 1 3 3 0 .5 3 9 44 .2 89 .8 28 .4 34 2
58 VIMALA 1 1 1 2 1 1 1 1 2 2 1 1 3 4 0 .46 4 8 .4 44 .4 94 28 .4 32 .4 2
59 KANAGARAJ 1 1 1 2 1 1 1 1 2 2 1 1 2 4 0 .51 4 6 .6 43 .2 92 29 .4 32 .2 2
60 PARAMAN 1 1 1 2 1 1 1 1 2 2 1 1 3 3 0 .48 3 7.8 42 .2 86 29 .8 32 .4 2
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INFORMED CONSENT 
Department of General Medicine 
COIMBATORE MEDICAL COLLEGE, COIMBATORE 
Principal Investigator : Dr. M. Gowri Sankar 
Research Guide  : Dr.S.Usha.M.D 
Organization                    :  Department of General Medicine 
Informed consent: I have been invited to participate in research project 
titled “HAEMATOLOGICAL MANIFESTATIONS IN 
CHRONIC OBSTRUCTIVE LUNG DISEASE IN 
RELATION TO FEV1 
 IN COIMBATORE MEDICAL COLLEGE HOSPITAL”, I 
understand, I will be answering a set of questionnaire, undergo physical 
examination, investigation and appropriate treatment. I also give consent 
to utilize my personal details for study purpose and can be contacted if 
necessary. 
I am aware that I have the right to withdraw at any time which will not 
affect my medical care. 
 
Name of the participant: 
Signature: 
Date: 
 
  
 
 
xg;Gjy; gbtk; 
 
ngah;  : 
ghypdk; :       taJ: 
Kfthp : 
 
 muR Nfhit kUj;Jtf; fy;Y}hpapy; nghJ kUj;Jtj; Jiwapy; 
gl;l Nkw;gbg;G gapYk; khzth; Nkw;nfhs;Sk; “%r;Rf;Foy;fs; 
milg;G fhuzkhf Kjy;; nehbapy; ntspj;js;Sk; %r;rpd; msitg; 
nghWj;Jk; kw;Wk; EiuaPuypd; khWjypdhYk; ,uj;jj;jpy; Vw;gLk; 
tpisTfs;” Fwpj;j Ma;tpy; nra;Kiw kw;Wk; midj;J 
tptuq;fisAk; Nfl;Lf; nfhz;L vdJ re;Njfq;fis njspTgLj;jpf; 
nfhz;Nld; vd;gij njhptpj;Jf; nfhs;fpNwd;. 
 ehd; ,e;j Ma;tpy; KO rk;kjj;JlDk;> Ra rpe;jidAlDk; 
fye;J nfhs;s rk;kjpf;fpNwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpguq;fs; 
ghJfhf;fg;gLtJld; ,jd; KbTfs; Ma;tpjopy; ntspaplg;gLtjpy; 
Ml;Nrgid ,y;iy vd;gij njhptpj;Jf; nfhs;fpNwd;. ve;j 
Neuj;jpYk; ,e;j Ma;tpypUe;J ehd; tpyfpf; nfhs;s vdf;F chpik 
cz;L vd;gijAk; mwpNtd;. 
 
,lk;:        ifnahg;gk; / Nuif 
ehs;: 
 
 
